USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
Disclosed herein are PTHrP or analogues thereof, such as abaloparatide, for preventing or reducing bone fractures in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to prevent or reduce bone fractures. Also disclosed are PTHrP or analogues thereof, such as abaloparatide, for increasing BMD and/or TBS in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to increase BMD and/or TBS.
1 . A method for preventing or reducing non-vertebral bone fractures in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a polypeptide of SEQ ID NO:1.
2 . A method for improving bone mineral density (BMD) and/or trabecular bone score (TBS) in a non-vertebral bone in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the polypeptide of SEQ ID NO:1.
3 . The method of claim 1 , wherein the non-vertebral bone is selected from the group consisting of wrist and hip bones.
4 . The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of an anti-resorptive agent.
5 . The method of claim 1 , wherein the polypeptide of SEQ ID NO: 1 is administered by subcutaneous injection.
6 . The method of claim 5 , wherein the therapeutically effective amount of the polypeptide of SEQ ID NO:1 is 80 μg.
7 . The method of claim 1 , wherein the subject is a woman.
8 . The method of claim 1 , wherein the subject has osteoporosis.
9 . (canceled)
10 . (canceled)
11 . The method of claim 7 , wherein the subject is a postmenopausal woman.
12 . The method of claim 1 , wherein the subject has high cortical porosity.
13 . A method for preventing or reducing non-vertebral bone fractures in a subject having high cortical porosity comprising administering to the subject a therapeutically effective amount of a polypeptide of SEQ ID NO:1.
14 . The method according to claim 13 , wherein the subject has a normal BMD.
15 . The method according to claim 13 , wherein the subject has a BMD T-score of at least about −1.
16 . (canceled)
17 . (canceled)
18 . The method according to claim 13 , wherein the therapeutically effective amount is 80 μg.
19 . The method according to claim 1 , wherein the polypeptide of SEQ ID NO:1 is administered via subcutaneous injection or transdermal delivery.
20 . The method according to claim 6 , wherein the polypeptide of SEQ ID NO:1 is administered via subcutaneous injection.
21 . The method according to claim 1 wherein the method results in a BMD increase of at least about 3% at one or more sites selected from the group consisting of spine, hip, and wrist.